1Fukui M,Nakano K,Shigeta H,et al.Anti-bodies to glutamic acid decarboxylase in Japanese diabetic patients with secondary oral hypoglycaemic therapy[J].Diabet Med,1997,14(2):148-152.
1Purrello F, Rabuazza AM. Metabolic factors that affect betacell function and survival. Diabet Nutr Metab, 2000, 13: 84-91.
2Sivitz WI. Lipotoxieity and glueotoxieity in type 2 diabetes. Effects on development and progression. Postgrad Med, 2001,109: 55-59,63-64.
3Lenhard M J, Reeves GD. Continous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med,2001,161: 2293-2300.
4Dupuy O, Mayaudon H, Palou M, et al. Optimized transient insulin infusion in uneontrolled type 2 Diabetes : Evaluation of a pragmatie attitude. Diabet Med, 2000,26 : 371-375.
5Valensi P, Moura I, Magoarou M,et al. Short-term effects of continuous subcutaneous insulin infusion treatment on insulin secretion in non-insulin-dependent overweight patients with poor glycaemic control despite maximal oral anti-diabetic treatment. Diabet Metab,1997,23: 51-57.
6Lormeau B, Aurousseau MH, Valensi P, et al. Hyperinsulinemia and hypofibrinolysis: effects of short-term optimized glyeemic control with contineuous insulin infusion in type Ⅱ diabetie patients. Metabolism,1997,46: 1074-1079.
7Ilkova H, Glaser B, Tunckale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care, 1997,20:1353-1356.
8Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 2001,44:929-945.
9Del Prato S, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes,2002, 51suppl 1: s109-116.
10Kahn SE. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med, 2000,108suppl 6a: 2s-8s.
6[4]Alvarsson M,Sundkvist G,Lager I,et al.Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients.Diabetes Care,2003,26(8):2231-2237.
7Weir GC,Bonner-Weir S.Five stage of evolving cell dysfunction during pro-Gression to diabetes.Diabetes,2004,53(l3):516-521.
8Olerup O.Zetterquist HHLA-DR typing by PCR amplification with sequence specific primers(PCR-SSP)in 2 hous:an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaverict ransplantation.Tis Antigens,1992,39(2):225.
9Wright A,Bureden AC,Paisey RB,et al.Sulfonylurea Inadeguacy:Efficacy of Addition of Insulin over 6 Years in Patient s with Type 2 Diabetes in t he U.K.Prospective Diabetes Study(U KPDS 57).Diabetes Care,2002,25(2):330-336.
10Khutsoane D,Sharma SK,Almustafa M,et al.Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting:experience from the PRESENT study.Diabetes Obes Metab,2008,10(3):212.
